Inhibition of human immunodeficiency virus type-1 by cdk inhibitors

Current therapy for human immunodeficiency virus (HIV-1) infection relies primarily on the administration of anti-retroviral nucleoside analogues, either alone or in combination with HIV-protease inhibitors. Although these drugs have a clinical benefit, continuous therapy with the drugs leads to dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Guendel, Irene, Agbottah, Emmanuel T, Kehn-Hall, Kylene, Kashanchi, Fatah
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2852372/
https://www.ncbi.nlm.nih.gov/pubmed/20334651
http://dx.doi.org/10.1186/1742-6405-7-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2852372/
https://www.ncbi.nlm.nih.gov/pubmed/20334651
http://dx.doi.org/10.1186/1742-6405-7-7

Ejemplares similares